Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 16839732)

1.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
2.

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.

3.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
4.

Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.

Vanitallie TB.

Metabolism. 2013 Jan;62 Suppl 1:S30-3. doi: 10.1016/j.metabol.2012.08.024. Epub 2012 Sep 26. Review.

PMID:
23021038
5.

Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.

Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Sorbi S, Pupi A.

J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):15-23.

6.

MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A.

Neurology. 2004 Dec 28;63(12):2332-40.

PMID:
15623696
7.

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H.

Ann N Y Acad Sci. 2007 Feb;1097:114-45. Review.

PMID:
17413016
8.

Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares.

Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, Liu X, Alexander GE, Bandy D, Caselli RJ, Reiman EM.

Neuroimage. 2012 May 1;60(4):2316-22. doi: 10.1016/j.neuroimage.2012.02.005. Epub 2012 Feb 12.

9.

Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.

Mosconi L, Nacmias B, Sorbi S, De Cristofaro MT, Fayazz M, Tedde A, Bracco L, Herholz K, Pupi A.

J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):370-6.

10.

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11.

11.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
12.

Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals.

Pihlajamäki M, Sperling RA.

Behav Neurol. 2009;21(1):77-91. doi: 10.3233/BEN-2009-0231.

PMID:
19847047
13.
14.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
15.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20. Review.

16.

Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8. Epub 2010 Jun 30.

17.

Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study.

Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Herholz K, Pupi A.

Psychiatry Res. 2004 Feb 15;130(2):141-51.

PMID:
15033184
18.

Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.

Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B; Alzheimer's Disease Neuroimaging Initiative.

PLoS Comput Biol. 2013 Apr;9(4):e1002987. doi: 10.1371/journal.pcbi.1002987. Epub 2013 Apr 4.

19.

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.

Small GW.

J Clin Psychiatry. 1996;57 Suppl 14:9-13. Review.

PMID:
9024331
20.

Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions.

Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A.

Neuroimage. 2008 Apr 15;40(3):1214-21. doi: 10.1016/j.neuroimage.2007.12.066. Epub 2008 Jan 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk